Inventor · disambiguated record
Joseph F. Arboleda-Velasquez
Also filed as: ARBOLEDA-VELASQUEZ JOSEPH · ARBOLEDA-VELASQUEZ JOSEPH F
7 granted patents·12 pending applications·4 citations·filing 2017–2024
75Inventor score
Files withSCHEPENS EYE RES INST14MASSACHUSETTS GEN HOSPITAL3CureVac SE1MASSACHUSETTS EYE & EAR INFIRMARY1
Top patents by PatentIndex Score
19 records- 0183US11229662B2Compositions and methods for the treatment of aberrant angiogenesisSCHEPENS EYE RES INST·Filed 2017·Granted Jan 25, 2022·2 cites·15 claims
- 0281US2025231200A1Blood Biomarkers and Diagnostic Methods for Small Vessel DiseasesSCHEPENS EYE RES INST·Filed 2024·Application pending·0 cites
- 0378US12188950B2Blood biomarkers and diagnostic methods for small vessel diseasesSCHEPENS EYE RES INST·Filed 2022·Granted Jan 7, 2025·0 cites·20 claims
- 0474US11739326B2RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transitionSCHEPENS EYE RES INST·Filed 2018·Granted Aug 29, 2023·1 cites·33 claims
- 0574US2025064977A1Nucleic Acid-Based Compositions and Methods for Treating Small Vessel DiseasesSCHEPENS EYE RES INST·Filed 2024·Application pending·0 cites
- 0673US12440443B2Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliverMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2023·Granted Oct 14, 2025·0 cites·20 claims
- 0771US11583497B2Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug deliverySCHEPENS EYE RES INST·Filed 2018·Granted Feb 21, 2023·1 cites·6 claims
- 0869US2024287165A1Apoe antibodies, fusion proteins and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2024·Application pending·0 cites
- 0969US2024301044A1Apoe antibodies, fusion proteins and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2024·Application pending·0 cites
- 1069US2024175022A1RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal TransitionSCHEPENS EYE RES INST·Filed 2023·Application pending·0 cites
- 1167US2022184109A1Compositions and methods for the treatment of aberrant angiogenesisSCHEPENS EYE RES INST·Filed 2021·Application pending·0 cites
- 1262US11453718B2NOTCH3 agonist compositions and methods for treating small vessel diseasesSCHEPENS EYE RES INST·Filed 2018·Granted Sep 27, 2022·0 cites·9 claims
- 1361US2023355611A1Topotecan for proliferative vitreoretinopathySCHEPENS EYE RES INST·Filed 2023·Application pending·0 cites
- 1460US2020103419A1Blood biomarkers and diagnostic methods for small vessel diseasesSCHEPENS EYE RES INST·Filed 2018·Application pending·0 cites
- 1559US12384834B2Anti-ApoE antibodies and polynucleotides thereofMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Aug 12, 2025·0 cites·22 claims
- 1658US2025099614A1Nucleic acid encoded transcription factor inhibitorsCureVac SE·Filed 2023·Application pending·0 cites
- 1752US2023190764A1Methods and Materials for Treatment of FibrosisSCHEPENS EYE RES INST·Filed 2021·Application pending·0 cites
- 1851US2023190959A1Nucleic acid-based compositions and methods for treating small vessel diseasesSCHEPENS EYE RES INST·Filed 2018·Application pending·0 cites
- 1949US2023310446A1Rho kinase inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transitionSCHEPENS EYE RES INST·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joseph F. Arboleda-Velasquez files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →